Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736835 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
A Phase 2 study of COVID-19, sponsored by CyanVac.
- Active
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 10
- Study locations
NCT05736835 is a Phase 2 study of COVID-19 that is active but no longer recruiting, run by CyanVac. The registered enrollment target is 227 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT05736835, a Phase 2 study of COVID-19, is active but no longer recruiting, sponsored by CyanVac.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will enroll up to 400 healthy participants, age 18-80 years.
Conditions Studied
Interventions
- BIOLOGICAL CVXGA
Study Locations (10)
New York
- University of Rochester - Rochester
- Velocity Clinical Research - Vestal
California
- Velocity Clinical Research - San Diego
Idaho
- Velocity Clinical Research - Boise
Iowa
- Velocity Clinical Research - Sioux City
Maryland
- Velocity Clinical Research - Rockville
Nebraska
- Velocity Clinical Research - Omaha
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Rhode Island
- Velocity Clinical Research - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05736835
The ClinicalTrials.gov registry entry for NCT05736835 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is CyanVac, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which CVXGA is the first listed.
NCT05736835 reports 10 study locations spanning 9 distinct geographic areas - top geographies include New York, California, Idaho.
Frequently Asked Questions
What is clinical trial NCT05736835 about?
NCT05736835 is a clinical study titled "A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults". The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will enroll up to 400 healthy participants, age 18-80 years.
What is the current status of trial NCT05736835?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2023-06-30. Estimated completion is 2028-06-30.
What conditions does trial NCT05736835 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05736835?
The interventions under investigation include: CVXGA (BIOLOGICAL).
Who is sponsoring clinical trial NCT05736835?
This trial is sponsored by CyanVac, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05736835 being conducted?
This trial has 10 study locations across California, Idaho, Iowa, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.